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Abstract
Background: The purpose of this study is to evaluate the importance 
of tenascin-C ( TNC), N-terminal pro brain natriuretic peptide (NT-
proBNP) and C-reactive protein (CRP) on LV remodelling after 
myocardial infarction (MI).
Methods: Fifty-seven stable patients with subacute anterior MI 
who had total or subtotal occlusion in the infarct-related left an-
terior desending artery in coronary angiography were enrolled the 
study. 18 of patients who had total occlusion received only medical 
theraphy, 19 of patients who had total occlusion received successful 
PCI+ medical theraphy and 20 of patients who had subtotal occlu-
sion received successful PCI+ medical theraphy. Left ventricular 
volumes and ejection fractions (EF) were measured with echocar-
diography. Serum TNC, NT-proBNP and CRP levels were mea-
sured at admission and a month after treatment.
Results: There was significant increase in LV end-diastolic vol-
ume (LVEDV) and LV end-systolic volume (LVESV) baseline to 
follow-up in total-PCI group. Baseline to follow-up;  a borderline 
significant increase was observed in LVEDV in the total-medical 
group. No significant difference was seen in LV volumes and EF in 
the subtotal-PCI group. NT-proBNP, TNC and CRP levels were de-
creased in all groups. The decrease in NT-proBNP and CRP values 
were significant in the total-medical and subtotal-PCI group but in 
the total-PCI group they were not significant. The decrease of TNC 
was significant in all groups but the lowest decrease was seen in the 
total-PCI group.
Conclusions: TNC, NT-proBNP and CRP reflect LV remodelling 
in accordance with echocardiography after MI.
Keywords: Tenascin-C; NT-pro BNP; CRP; Remodelling; Myo-
cardial infarction
Introduction
Fibrinolytic therapy or primary percutaneous coronary inter-
vention (PCI) is early reperfusion strategies to treat ST seg-
ment elevation myocardial infarction (MI). However these 
strategies cannot be performed in about one third of patients 
because of late presentation [1]. Therefore, the management 
of patients experiencing late phase MI is an important clini-
cal issue. Previous studies showed that PCI had no clinical 
benefit for patients with total occlusion of the infarct-related 
coronary artery [2-4]. Based on these studies we aimed to 
confirm the unfavorable effect of PCI on total occlusion af-
ter MI with cardiac biomarkers such as tenascin-C (TNC), 
N-terminal pro brain natriuretic peptide (NT-proBNP) and 
C-reactive protein (CRP).  TNC is an extracellular matrix 
glycoprotein that is expressed in various cardiac pathologi-
cal conditions, including; MI [5, 6], myocarditis [7], hi-
bernating myocardium and LV (LV) remodeling [8]. Brain 
natriuretic peptide (BNP) is a cardiac neurohormone that is 
secreted from the ventricular myocardium. It is secreted as a 
response to increased LV wall stress and is related with LV 
systolic dysfunction [9] and progressive remodeling after MI 
[10]. Persistent high plasma BNP levels after MI indicate LV 
remodeling and progressive heart failure. C- reactive protein 
(CRP) is a marker commonly  used to show acute inflamma-
tory response. It has also been used to demonstrate ventricu-
lar remodeling after acute MI [11].
In this study, we aimed to demonstrate the usefullness 
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of TNC, NT-proBNP and CRP on LV remodeling after MI.
Methods
Study population
Fifty-seven patients with subacute anterior wall MI were en-
rolled in the study. Exclusion criteria included the following: 
patients who had received fibrinolytic therapy or who had 
PCI performed in the early stages of MI, any findings sug-
gesting ongoing myocardial ischemia, angina at rest, NYHA 
class III or IV heart failure, shock, a serum creatinine con-
centration higher than 2.5 mg per deciliter, angiographically 
significant left main or three-vessel coronary artery disease, 
any significant stenosis in the right or circumflex coronary 
artery together with an LAD artery lesion, history of coro-
nary artery disease, cardiac muscle disease, bundle branch 
block or atrial fibrillation, hemodynamic and electrical insta-
bility. Unsuccessful PCI was also an exclusion criterion in 
the groups to which PCI was applied.
Conventional coronary angiography was performed with 
Philips Integris 5000 equipment (Philips Medical Systems, 
Best, The Netherlands) in patients within 1 to 3 days after 
admission. After obtaining images by standard approaches, 
each angiogram was interpreted by two independent cardi-
ologists. The coronary lesions were classified as total oc-
clusions or subtotal occlusive lesions. The criterion for to-
tal occlusion of the LAD artery was absent antegrade flow, 
defined as a Thrombolysis in Myocardial Infarction (TIMI) 
flow grade of 0.
Patients were divided into three groups according to 
their angiographic characteristics and treatment options. The 
total-PCI group consisted of 18 patients with total occlusion 
Table 1. Baseline Characteristics of All Patients in Three Groups
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. DM: diabetes mellitus; HT: hyper-
tension; CVD: cerebrovascular disease; LDL-C: low density lipoprotein; HDL-C: high density lipoprotein; T.CHOL: total 
cholesterol; TG: trigliseride
Total-PCI  Group 
(n: 18)
Total-Medical 
Group (n: 19)
Subtotal-PCI  
Group (n: 20)
P value
Age 62 ± 12 65 ± 8 59 ± 12 0.2
Female (n, %) 5 (27) 6 (31) 6 (30) 0.9
DM (n, %) 8 (44) 9 (47) 4 (20) 0.1
HT (n, %) 9 (50) 10 (52) 6 (30) 0.3
Smoke (n, %) 11 (61) 10 (52) 12 (60) 0.8
CVD (n, %) 1 (5) 2 (10) 0 0.3
NYHA Class (n, %)
I 7 (39) 8 (42) 9 (45) 0.9
          II 11(61) 11(58) 11(55) 0.9
       III- IV 0 0 0
Blood Pressure(mmHg)
    Diastolic 82 ± 18 85 ± 15 75 ± 11 0.1
    Systolic 133 ± 23 137 ± 28 125 ± 22 0.3
Creatinine (mg/dL) 1.0 ± 0.2 1.1 ± 0.4 0.9 ± 0.1 0.1
Lipid profile (mg/dL)
LDL-C 120 ± 29 116 ± 43 118 ± 34 0.9
HDL-C 39 ± 9 41 ± 10 37 ± 8 0.4
T.CHOL 192 ± 46 183 ± 54 184 ± 42 0.8
TG 165 ± 131 129 ± 89 144 ± 80 0.5
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Table 2. The Change of Cardiac Biomarkers at Baseline and First Month in All Groups
Table 3. The Change of LV Volumes and Functions Baseline to First Month in All Groups
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. NT-proBNP: N- terminal 
natriuretic peptide; CRP: C-reaktive protein
Data expressed as mean ± SD, P < 0.05 was accepted as a statistically significant. LVEDV: Left ventricular end-
diastolic volume; LVESV: Left ventricular endsystolic volume; LVEF: Left ventricular ejection fraction
Total- PCI Group (n = 18) Baseline First month P value
TENASCİN- C (ng/mL) 24 ± 12 14 ± 8 0.01
NT-PROBNP  (pg/mL) 14311 ± 6962 11249 ± 5918 0.08
CRP (mg/dL) 24 ± 6 10 ± 2 0.07
Total-Medical Group (n = 19)
TENASCİN-C (ng/mL) 21 ± 8 13 ± 4 < 0.001
NT-PROBNP (pg/mL) 12284 ± 7527 3661 ± 3973 < 0.001
CRP (mg/dL) 82 ± 12 8 ± 6 0.003
Subtotal-PCI Group (n = 20)
TENASCİN-C (ng/mL) 22 ± 7 13 ± 5 < 0.001
NT-PROBNP (pg/mL) 15329 ± 6281 5305 ± 6141 < 0.001
CRP (mg/dL) 23 ± 4 5 ± 2 0.004
 
Total- PCI Group (n = 18) Baseline First month P value
LVESV (mL/mm2) 59 ± 27 68 ± 26 0.03
LVEDV (mL/mm2) 98 ± 35 114 ± 35 0.01
LVEF (%) 39 ± 8 40 ± 8 0.1
Total-Medical Group (n = 19)
LVESV (mL/mm2) 75 ± 23 82 ± 25 0.1
LVEDV (mL/mm2) 113 ± 27 126 ± 29 0.05
LVEF (%) 35 ± 9 36 ± 9 0.2
Subtotal-PCI Group (n = 20)
LVESV (mL/mm2) 66 ± 30 68 ± 32 0.4
LVEDV (mL/mm2) 113 ± 40 115 ± 38 0.5
LVEF (%) 42 ± 9 42 ± 9 0.3
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in the LAD artery in whom PCI was performed together with 
medical therapy. The total-medical group consisted 19 pa-
tients with total occlusion in LAD and received only medical 
therapy. The subtotal-PCI group consisted 20 patients who 
had subtotal occlusion in the LAD artery in whom PCI was 
performed together with medical therapy. The patients in the 
total-PCI and subtotal-PCI groups were assigned to PCI with 
stent placement. Optimal medical therapy included aspirin, 
angiotensin converting enzyme inhibitors, beta-blockers, 
lipid lowering therapy, and clopidogrel.
In the total-PCI and subtotal-PCI groups, PCI was per-
formed at 2 - 28 days after MI. Successful PCI was defined 
Figure 1. The change of tenascin-C levels between baseline and first month in 
all study groups. (Group 1: Total-PCI group; Group 2: Total-medical group; Group 
3: Subtotal-PCI group; BL: baseline; FM: first month)
Figure 2. The change of NT-proBNP levels between baseline and first month in 
all study groups. (Group 1: Total-PCI group; Group 2: Total-medical group; Group 
3: Subtotal-PCI group; BL: baseline; FM: first month)
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as an open artery with residual stenosis of less than 30% and 
a TIMI flow grade of 3. The study was approved by the local 
ethics committee.  All the patients were informed about the 
study, and their written consent forms were obtained.
Echocardiography
The Echocardiographies were performed by two cardiology 
specialist with Vivid 7 instruments (GE Medical Systems, 
Milwaukee, WI, USA), with a 2.5 MHz transducer and har-
monic imaging in the cardiology department’s echocardiog-
raphy laboratory. LV end diastolic (LVEDV) and end systol-
ic volumes (LVESV) were measured at apical four chambers 
view. LV ejection fraction (LVEF) was assessed using the 
modified biplane Simpson’s method.
Statistical analysis
Data are expressed as mean ± SD, or as a percentage. Com-
parisons between the groups were carried out using a One-
way Anova test. To compare the change in measurements be-
tween baseline and at one month in each group,  a Student’s   
paired test was used.  SPSS 15.0 software was used for sta-
tistical analysis (Version 15, SPSS Inc., Chicago, IL, USA).
 
Results
The demographic characteristics of the patients were similar 
in all groups (Table 1).
In the total-PCI and subtotal-PCI groups, the average of 
mean times from MI to intervention was 5 days.
The NT-proBNP, TNC and CRP levels were decreased 
in all groups at one month compared to baseline values. TNC 
levels were significantly decreased at one month in all three 
groups. NT-proBNP and CRP values were not significantly 
decreased in the total-PCI group but were significantly de-
creased in both the total-medical and subtotal-PCI groups at 
one month (Table 2).
In  the  total-PCI  group,  no  significant  difference  was 
found between baseline and first month in LVEF. However, 
a significant increase was observed in LVEDV and LVESV 
(Table 3). No significant difference was found at follow-up 
comparing to the baseline values in LVESV, LVEDV and 
LVEF in the subtotal-PCI group (Table 3).
Comparing to the baseline values; LVESV and LVEF 
were not significantly changed at the first month in the total-
medical group (Table 3). A borderline significant increase 
was  observed  in  LVEDV  at  the  first  month  compared  to 
baseline measurement (LVEDV: 113 ± 6 mL versus 126 ± 6 
mL, P = 0.05).
Figure 1 shows the change of tenascin-C levels in the 
three groups. The lowest decrease in the levels of TNC were 
seen in the total-PCI group at one month after MI.
Figure 2 shows the change in NT-pro BNP levels in the 
three groups. At first month after MI, the lowest decrease 
NT-pro BNP levels was seen in the total-PCI group.
Discussion
  
Using PCI to treat infarct-related artery occlusion in stable 
patients is still a controversial issue. We assessed the effect 
of PCI and optimal medical therapy in patients with total 
or subtotal occlusion in an infarct-related LAD artery. Our 
present results showed that PCI applied to total occlusion 
in an infarct-related LAD artery caused higher LV remodel-
ing when compared to medical therapy for total occlusion 
and PCI for total occlusion. These results emphasize the im-
portance of avoiding invasive intervention in stable patients 
with total occlusion in the infarct-related LAD artery. For 
many years, the open artery hypothesis was defended as a 
treatment that would improve LV functions and reduce LV 
remodeling after late reperfusion [12, 13]. However, in re-
cent years, large randomized studies demonstrated no clini-
cal benefit from percutaneous coronary intervention for a to-
tally occluded infarct-related artery in asymptomatic patients 
who had hemodynamically and electrically stable clinical 
findings and who did not have evidence of severe ischemia 
[2, 4, 14, 15].  Based on these results, current guidelines do 
not recommend PCI for a totally occluded infarct-related ar-
tery in asymptomatic patients [16].
On the other hand, we analyzed the effect of cardiac bio-
markers on LV remodeling in stable patients after MI. Thus, 
we aimed to compare the biochemical data of remodeling in 
patients in whom PCI was applied for the treatment of a total 
or subtotal occlusion infarct-related artery after MI.
Tenascin-C is used as a marker that shows LV remod-
eling and long-term prognosis after MI [8]. Increased TNC 
levels had a relationship with complexity of coronary lesion 
after MI [17], severity of heart failure and LV remodelling 
in dilated cardiomyopathy [18]. CRP and neurohormones, 
which were secreted from cardiomyocytes like atrial natri-
uretic peptides (ANP) and brain natriuretic peptides (BNP), 
are also used to show LV remodeling [10, 11]. We aimed to 
show LV remodeling with biomarkers such as TNC, NT-pro 
BNP and CRP. Compared to the baseline values, NT pro-
BNP, TNC and CRP levels were decreased in all groups 
at one month. In the total- PCI group the decrease of NT-
proBNP and CRP values was not statistically significant but 
the TNC values were significantly decreased. Hovewer, the 
rate of decrease in TNC levels was lower in the total-PCI 
group than in the other groups. In both the total-medical and 
subtotal-medical groups, there were significant decreases in 
the TNC, NT-proBNP and CRP values at one month.
Like the values of LV volumes and EF on echocardiog-
raphy; serum levels of TNC, NT-proBNP and CRP showed 
the LV remodelling after MI. This study is very important 
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to demonstrate the LV remodelling with cardiac biomarkers.
Our study’s most important limitation was the small 
number of patients. Follow-up time was only one month. 
Therefore, large and long-term follow-up studies are needed.
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